At2g03980 Antibody
Description
Definition and Basic Characteristics
The At2g03980 Antibody targets the protein product of the At2g03980 gene in Arabidopsis thaliana. This gene is annotated as encoding a "similar to unknown protein," indicating its functional role remains under investigation . The antibody is classified as a polyclonal reagent, optimized for detecting the target protein in immunological assays such as Western blotting or immunofluorescence .
Genomic and Functional Insights
-
The At2g03980 gene is located on chromosome 2 of Arabidopsis thaliana .
-
Functional annotation suggests potential roles in metabolic or signaling pathways, though no direct experimental evidence is publicly documented .
-
Homology searches reveal weak similarities to uncharacterized proteins in other plant species, highlighting its conserved but enigmatic nature.
Research Applications
The At2g03980 Antibody enables:
-
Protein Localization Studies: Tracking subcellular distribution in plant tissues .
-
Expression Profiling: Monitoring developmental or stress-induced changes in protein levels.
-
Interaction Screens: Identifying binding partners via co-immunoprecipitation (Co-IP).
Challenges and Limitations
-
Uncertain Target Function: The lack of functional annotation for At2g03980 complicates hypothesis-driven research .
-
Validation Data: Public databases (e.g., UniProt, TAIR) lack peer-reviewed studies using this antibody, necessitating independent validation by users.
-
Species Specificity: Reactivity is confirmed only in Arabidopsis thaliana; cross-reactivity with other plants is untested .
Future Directions
-
CRISPR/Cas9 Knockout Models: Pairing the antibody with mutant lines to elucidate gene function.
-
Proteomic Integration: Combining with mass spectrometry for pathway mapping.
-
Comparative Studies: Profiling expression across plant species to infer evolutionary roles.
Critical Considerations for Users
-
Always include positive/negative controls (e.g., Arabidopsis wild-type vs. at2g03980 mutants).
-
Optimize antibody dilutions empirically due to batch variability.
-
Cross-validate findings with orthogonal methods (e.g., RNA-seq for expression patterns).
Product Specs
Target Background
KEGG: ath:AT2G03980
UniGene: At.42977
Q&A
FAQs for Researchers on ARG2 (Arginase 2) Antibodies
(Note: The query refers to "At2g03980 Antibody," but no direct data exists in the literature for this Arabidopsis thaliana gene identifier. Based on contextual alignment with ARG2 (Arginase 2), a human homolog implicated in tumor immunology, the below FAQs address antibody development and mechanistic insights for ARG2-related research. Adjustments may be needed for plant-specific systems.)
What experimental strategies resolve contradictions in antibody inhibition potency between scFv and IgG formats?
Advanced Analysis:
-
Structural Dynamics: Compare Fab-ARG2 co-crystal structures (e.g., C0020187 vs. C0021158) to identify steric or conformational changes. Affinity maturation improved C0021158’s IC₅₀ from >2 µM to 18.5 nM by altering CDR loops .
-
Valency Effects: Trimeric ARG2 requires three Fab binders for full inhibition. Use HTRF® competitive binding assays to assess epitope overlap and cooperative binding .
-
Table: Key Parameters for Antibody Optimization
How do non-competitive inhibitory mechanisms of ARG2 antibodies impact therapeutic design?
Mechanistic Insight:
-
Allosteric Modulation: C0021158 reduces ARG2’s Vmax without affecting KM, confirmed by substrate titration assays. This suggests binding to regulatory sites distant from the catalytic center .
-
Structural Evidence: X-ray crystallography revealed antibody-induced reorientation of Arg39, sterically blocking L-arginine access and altering His160 pKa .
-
Therapeutic Implications: Non-competitive inhibitors avoid substrate competition, enabling synergy with small-molecule therapies targeting the active site.
What methods assess preexisting anti-antibody responses in preclinical models?
Technical Guidance:
-
Total ATA Assays: Use bridging ELISA to detect anti-CDR and anti-framework antibodies. For example, anti-DLL4 F(ab′)₂ hinge reactivity was quantified in cynomolgus serum .
-
Competition Assays: Differentiate anti-CDR antibodies by spiking with control F(ab′)₂. Sensitivity thresholds (e.g., 500 ng/mL) ensure specificity .
How are in silico tools integrated into antibody development workflows?
Advanced Application:
-
Docking Simulations: Predict L-arginine mimetic binding in the presence of antibodies (e.g., C0021158’s steric blockade) .
-
MD Simulations: Model CDR loop flexibility during affinity maturation to prioritize mutations (e.g., non-conservative substitutions in CDR-H2) .
What controls are critical for in vivo validation of ARG2 antibodies?
Experimental Design:
